They can't force the company to pay the dividend. The board votes on that every quarter. The existing board still has a large majority. I do expect the new members to have a voice on the board, but they will be a minority.
Even though I want my dividends, clearly it's in the best interest of the company to use existing cash to start phase 3. I doubt that many people would expect the company to delay the start of phase 3. The money to pay the preferred shareholders should come from a partnership, or even better, a buyout. But phase 3 needs to kick off ASAP.
The company would jump for joy if the preferred shareholders converted their shares. A preferred shareholder can do that now, but it doesn't make sense to do so. And it would help the company, not hurt it.
I see the preferred and common shareholders as having a similar objective right now. Everybody needs the company to succeed to have their investment pay off - and nobody is happy with the share price. I know there are always some people who claim to be in for the long term and say that they don't care what the stock price does short term. To some extent, I can agree. But that wears thin after a while.
It won't be too long until the common shareholders will be clamoring (as much or more so) for the company to strike a deal to get some cash and to get the share price up. We don't know what Spiro is hearing, but I'm guessing that the large shareholders are already giving him a gentle nudge to do something to gain Wall Street confidence and get the share price up. If they diluted now (I don't expect that), it would probably get ugly. I expect a partnership.
Recent CYCC News
- Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/08/2024 01:15:00 PM
- Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules • GlobeNewswire Inc. • 05/02/2024 08:30:00 PM
- $8 Million Private Placement Announcement Sends Biotech Flying • AllPennyStocks.com • 04/30/2024 05:51:00 PM
- Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer • GlobeNewswire Inc. • 04/01/2024 01:15:00 PM
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/19/2024 08:05:00 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/13/2024 08:05:00 PM
- Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/07/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit • GlobeNewswire Inc. • 03/06/2024 02:15:00 PM
- Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer • GlobeNewswire Inc. • 01/30/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Cyclacel Pharmaceuticals Announces Reverse Stock Split • GlobeNewswire Inc. • 12/12/2023 09:05:00 PM
- Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC • GlobeNewswire Inc. • 11/30/2023 02:15:00 PM
- Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 11/28/2023 10:15:00 PM
- Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 02:15:00 PM
- Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/09/2023 08:05:00 PM
- Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/03/2023 01:15:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM